Loading...
XJPX
4512
Market cap65mUSD
Oct 09, Last price  
301.00JPY
1D
0.33%
1Q
7.89%
Jan 2017
20.88%
Name

Wakamoto Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XJPX:4512 chart
P/E
45.98
P/S
1.05
EPS
6.55
Div yield, %
1.00%
Shrs. gr., 5y
—
Rev. gr., 5y
2.18%
Revenues
9.91b
+27.18%
10,181,164,00010,081,276,0009,779,708,0009,671,815,0009,429,946,0009,924,168,00010,314,297,00010,613,425,00011,194,262,00010,833,025,00010,900,874,00010,741,975,00010,917,899,0008,894,837,0008,383,144,0008,660,377,0007,738,426,0007,789,462,0009,906,841,000
Net income
227m
+252.60%
406,893,000351,361,00048,518,000-425,505,000-222,170,000183,344,000844,791,00083,343,00020,512,00094,745,000125,956,000-181,280,000-1,656,539,000-601,856,000238,543,000138,256,000108,959,00064,440,000227,215,000
CFO
-487m
L-17.81%
894,171,000824,582,000489,390,000346,513,000589,256,0001,199,890,0001,629,172,0001,175,302,000594,303,0001,098,285,000555,706,000-114,493,000-155,064,000163,438,000339,174,000631,920,000-107,338,000-592,454,000-486,912,000
Dividend
Mar 30, 20273.5 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.

Key people

Kimihiko Sato
Managing Director, Chief Director of Healthcare Business · since 2024
Noboru Yamazaki
Senior Executive Officer, Manager of Business Planning · since 2023
Kenichi Shigetoshi
Executive Officer, Chief Director of Global Business, Director of International Sales, Director of Sales Planning · since 2025
Sunao Ehara
Executive Officer
Hiroaki Hayashi
Executive Officer, Director of Reliability Assurance · since 2024
Shigeo Kimura
Executive Officer, Director of Pharmaceutical Sales · since 2025
Mizuho Koike
Executive Officer, Director of Accounting · since 2023
Hiroyoshi Kasai
Chief Director of Pharmaceutical Development, Director of Pharmaceutical Development, Director of Product Strategy, Director · since 2023
Makoto Taniguchi
Chief Director of Production, Sagami Oi Plant Manager, Director · since 2024
Tomoyuki Hirai
Managing Director, Chief Director of Administration, Director of General Affairs, Manager of Business Planning Office, Manager of Sustainability Promotion Office · since 2024
Haruhisa Hirata
Director · since 2009
Arata Igarashi
President, Representative Director · since 2022
Katsuyoshi Ejima
Independent Director · since 2017
Kana Hikawa
Independent Director · since 2024
Ikuro Kuwahara
Independent Director · since 2023
URL
http://www.wakamoto-pharm.co.jp
IPO date
May 16, 1949
Employees
403
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT